Kestra Medical Technologies (KMTS) insider schedules sale of 8,752 vested shares

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) has a notice from insider Traci Umberger indicating an intent to sell up to 8,752 shares of common stock through Merrill Lynch on or after July 31, 2026 on NASDAQ. These shares are tied to the July 17, 2026 vesting of performance share unit awards, granted as part of the company’s equity compensation program.

The filing also reports that Umberger sold 5,887 shares of common stock on July 30, 2026 for 133,892.22 during the prior three months, providing recent trading history associated with this insider’s holdings.

Key Figures

Proposed shares to be sold: 8,752 shares Estimated aggregate value of proposed sale: 197,837.19 Shares sold in prior 3 months: 5,887 shares +2 more

5 metrics

Proposed shares to be sold 8,752 shares Common stock planned to be sold through Merrill Lynch on or after July 31, 2026

Estimated aggregate value of proposed sale 197,837.19 Aggregate value associated with 8,752 shares of common stock

Shares sold in prior 3 months 5,887 shares Common stock sold on July 30, 2026

Value of prior sale 133,892.22 Total consideration for 5,887 shares sold on July 30, 2026

PSU vesting date 07/17/2026 Vesting of performance share unit awards underlying the shares

Key Terms

Form 144, performance share unit awards, equity compensation

3 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

performance share unit awards financial

"Vesting of performance share unit awards | KESTRA MEDICAL TECHNOLOGIES"

equity compensation financial

"Granted as part of issuer equity compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:30 PM Accepted by SEC EDGAR 07/31/2026 - 04:29 PM Learn about SEC filing dates

FAQ

What does the Form 144 filing for KMTS disclose about planned stock sales?

The Form 144 indicates an intent to sell up to 8,752 shares of Kestra Medical Technologies common stock through Merrill Lynch on or after July 31, 2026 on NASDAQ, following the vesting of equity awards.

How many KMTS shares is Traci Umberger planning to sell under this Form 144?

Traci Umberger plans to sell up to 8,752 shares of Kestra Medical Technologies common stock. These shares relate to performance share unit awards vesting on July 17, 2026 and are to be sold through Merrill Lynch on NASDAQ.

What prior KMTS stock sale is reported in the last three months?

The filing reports that Traci Umberger sold 5,887 KMTS shares of common stock on July 30, 2026 for total consideration of 133,892.22, providing recent trading activity for this insider over the preceding three months.

What is the estimated value of the KMTS shares covered by the planned sale?

The proposed sale of 8,752 KMTS shares has an indicated aggregate value of approximately 197,837.19, based on the figures in the notice. This reflects the estimated market value associated with the intended Form 144 sale.

How were the KMTS shares in the Form 144 obtained by the insider?

The shares relate to the vesting of performance share unit awards on July 17, 2026, which were granted as part of issuer equity compensation by Kestra Medical Technologies to the reporting insider.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	8752	197837.19	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			8752	07/17/2026	Granted as part of issuer equity compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Traci Umberger 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	5887	133892.22

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)